Our industry-leading neuroscience portfolio includes FDA-approved treatments for major depressive disorder, agitation associated with dementia due to Alzheimer's disease, excessive daytime sleepiness associated with narcolepsy and obstructive sleep apnea, and migraine, as well as multiple novel product candidates addressing a broad range of serious neurological and psychiatric conditions that impact over 150 million people in the United States. Publications, Medical Affairs, HEOR, Field Medical) to interpret complex data to develop high-quality strategic scientific documents including congress abstracts, posters, and oral presentations, slide decks, and manuscripts that align to the Medical Affairs strategy.